

# Rodger E Tiedemann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8015822/publications.pdf>

Version: 2024-02-01

87  
papers

3,755  
citations

346980

22  
h-index

145109

60  
g-index

89  
all docs

89  
docs citations

89  
times ranked

6242  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 23-30.	1.4	0
2	sciCNV: high-throughput paired profiling of transcriptomes and DNA copy number variations at single-cell resolution. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	6
3	A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 333-342.	1.1	0
4	Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 5401-5414.	3.2	16
5	Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e506-e509.	0.2	1
6	Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11129-11147.	2.9	12
7	Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size. <i>Blood</i> , 2021, 138, 460-460.	0.6	1
8	Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1837-1837.	0.6	1
9	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2021, 138, 3055-3055.	0.6	2
10	Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020, 55, 578-585.	1.3	17
11	<i>Listeria</i> Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy. <i>JAMA Oncology</i> , 2020, 6, 293.	3.4	9
12	Syngeneic transplants for multiple myeloma – a single center experience and review of the literature. <i>Leukemia and Lymphoma</i> , 2020, 61, 3519-3522.	0.6	0
13	An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines. <i>Leukemia and Lymphoma</i> , 2020, 61, 1860-1868.	0.6	1
14	Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. <i>Cancer Research</i> , 2019, 79, 5536-5549.	0.4	17
15	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2576-2579.	0.6	0
16	Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma – A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195-e203.	0.2	4
17	Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study. <i>Blood</i> , 2019, 134, 4570-4570.	0.6	1
18	Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. <i>Blood</i> , 2019, 134, 5704-5704.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation. <i>Blood</i> , 2019, 134, 62-62.	0.6	2
20	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 225-234.	0.2	7
21	Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience. <i>Blood</i> , 2018, 132, 4614-4614.	0.6	0
22	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR $\epsilon$ CD) for untreated low $\epsilon$ grade non $\epsilon$ Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	2.0	15
23	Secondary primary malignancies during the lenalidomide $\epsilon$ dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017, 6, 3-11.	1.3	24
24	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394.	0.2	11
25	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016, 128, 2137-2137.	0.6	3
26	Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite $\epsilon$ , $\epsilon$ Chain (HLC) Ratio Assessments. <i>Blood</i> , 2016, 128, 4632-4632.	0.6	1
27	Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy. <i>Blood</i> , 2016, 128, 5821-5821.	0.6	3
28	Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 3457-3457.	0.6	0
29	Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab Na $\epsilon$ Ve Patients?. <i>Blood</i> , 2016, 128, 1795-1795.	0.6	0
30	Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2015, 50, 204-208.	1.3	43
31	Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2668-2673.	0.6	27
32	CyBorD induction therapy in clinical practice. <i>Bone Marrow Transplantation</i> , 2015, 50, 375-379.	1.3	21
33	Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 $\epsilon$ mL per injection site. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 285-292.	0.5	9
34	Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults. <i>British Journal of Haematology</i> , 2015, 170, 384-390.	1.2	7
35	Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. <i>Bone Marrow Transplantation</i> , 2015, 50, 95-99.	1.3	42
36	Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 232-235.	0.6	12

#	ARTICLE	IF	CITATIONS
37	Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience. <i>Blood</i> , 2015, 126, 1842-1842.	0.6	0
38	Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Heavy/light chain (HLC) Normalization. <i>Blood</i> , 2015, 126, 1982-1982.	0.6	0
39	Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience. <i>Blood</i> , 2015, 126, 5361-5361.	0.6	0
40	Getting to the root of the problem: the causes of relapse in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 251-254.	1.1	9
41	Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution. <i>British Journal of Haematology</i> , 2014, 164, 722-728.	1.2	22
42	Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival. <i>Leukemia and Lymphoma</i> , 2014, 55, 2284-2289.	0.6	13
43	BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. <i>Leukemia</i> , 2014, 28, 1657-1665.	3.3	171
44	Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2014, 167, 563-565.	1.2	41
45	The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2014, 124, 396-396.	0.6	27
46	A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 4410-4410.	0.6	1
47	Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience. <i>Blood</i> , 2014, 124, 4756-4756.	0.6	1
48	Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4773-4773.	0.6	8
49	Clinical Characteristics and Treatment Outcomes in Patients Diagnosed with Primary Mediastinal Large B-Cell Lymphoma at Princess Margaret Cancer Centre from 1994-2012. <i>Blood</i> , 2014, 124, 4447-4447.	0.6	0
50	Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. <i>British Journal of Haematology</i> , 2013, 162, 483-488.	1.2	89
51	Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma. <i>Cancer Cell</i> , 2013, 24, 289-304.	7.7	298
52	Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. <i>Leukemia</i> , 2013, 27, 2357-2365.	3.3	142
53	Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 555-560.	0.6	11
54	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2013, 122, 3231-3231.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Follicular Lymphoma In Young Adults: Clinical Characteristics and Early Treatment Outcomes. Blood, 2013, 122, 4273-4273.	0.6	1
56	Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) For The Treatment Of Secondary Plasma Cell Leukaemia. Blood, 2013, 122, 5398-5398.	0.6	1
57	Early Relapse After Single ASCT For MM Patients Is a Major Predictor Of Survival In The Era Of Novel Agents. Blood, 2013, 122, 3396-3396.	0.6	0
58	Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years. Blood, 2013, 122, 5315-5315.	0.6	0
59	Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome. Cancer Research, 2012, 72, 757-768.	0.4	113
60	Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival. Blood, 2012, 120, 595-595.	0.6	1
61	RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood, 2011, 117, 3847-3857.	0.6	97
62	RNAi Screening Identifies BCL-XL As An Erythroid Lineage-Specific 5-Azacytidine Sensitizer While the BCL-2/BCL-XL/BCL-W Inhibitor ABT-737 Results in More Universal Sensitization in Leukemia Cells,. Blood, 2011, 118, 3513-3513.	0.6	3
63	Central Nervous System (CNS) Involvement with Multiple Myeloma (MM) â€“ Longterm Survival Can Be Achieved with Radiation, Intrathecal (IT) Chemotherapy, and Immunomodulatory Agents (IMiDs),. Blood, 2011, 118, 3983-3983.	0.6	1
64	Bortezomib-Based Therapy without Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t(4;14): A Canadian National Trial,. Blood, 2011, 118, 3982-3982.	0.6	0
65	Absolute Lymphocyte Count As Predictor of Overall Survival for Patients with Multiple Myeloma Treated with Single Autologous Stem Cell Transplant: Experience of a Single Centre,. Blood, 2011, 118, 4121-4121.	0.6	0
66	Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood, 2010, 115, 1594-1604.	0.6	95
67	Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 2010, 115, 3416-3417.	0.6	179
68	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“2. Mayo Clinic Proceedings, 2010, 85, 197-199.	1.4	5
69	Identification of a potent natural triterpenoid inhibitor of proteasome chymotrypsin-like activity and NF-Î²B with antimyeloma activity in vitro and in vivo. Blood, 2009, 113, 4027-4037.	0.6	90
70	A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity,. Blood, 2009, 114, 616-616.	0.6	2
71	Kinome-Wide RNAi Studies in Human Multiple Myeloma Identify a Lymphoid Restricted Kinase GRK6 as a Selectively Vulnerable Target That Regulates STAT3/MCL1.. Blood, 2009, 114, 601-601.	0.6	0
72	RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.. Blood, 2009, 114, 602-602.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Achilles Heel Molecular Vulnerabilities in Multiple Myeloma Identified From Genome-Scale RNA Interference Screening.. Blood, 2009, 114, 2801-2801.	0.6	0
74	Comparative Genomic Hybridization, Gene Expression Profiling and Whole Genome Sequencing Analysis of Disease Progression in Myeloma Reveals Vigorous Clonal Evolution in Patients with High Baseline Genetic Risk.. Blood, 2009, 114, 2810-2810.	0.6	0
75	Genetic aberrations and survival in plasma cell leukemia. Leukemia, 2008, 22, 1044-1052.	3.3	299
76	AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies. Cancer Cell, 2008, 13, 167-180.	7.7	322
77	Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood, 2008, 112, 760-769.	0.6	47
78	Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. Journal of Clinical Investigation, 2008, 118, 1750-64.	3.9	52
79	Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 2007, 109, 5430-5438.	0.6	209
80	A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood, 2007, 110, 4047-4054.	0.6	54
81	Promiscuous Mutations Activate the Noncanonical NF- $\kappa$ B Pathway in Multiple Myeloma. Cancer Cell, 2007, 12, 131-144.	7.7	941
82	PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NF $\kappa$ B.. Blood, 2007, 110, 671-671.	0.6	1
83	High Resolution Array CGH Identifies TRAF3 as a Novel Tumor Suppressor in Multiple Myeloma.. Blood, 2006, 108, 3407-3407.	0.6	0
84	Kinetin Riboside Is a Novel Targeted Inhibitor of CCND1 and CCND2 Transactivation with Substantial Preclinical Anti-Myeloma Activity.. Blood, 2006, 108, 367-367.	0.6	0
85	Chemical Library Screening Identifies Novel Inhibitors of Cyclin D2 (CCND2) Transactivation That Selectively Induce Apoptosis in Multiple Myeloma Cells.. Blood, 2006, 108, 3421-3421.	0.6	0
86	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. Blood, 2006, 108, 3587-3587.	0.6	0
87	The Superantigen Streptococcal Pyrogenic Exotoxin C (SPE-C) Exhibits a Novel Mode of Action. Journal of Experimental Medicine, 1997, 186, 375-383.	4.2	76